Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1275
Title: | A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D. |
Epworth Authors: | Jolly, David Dunn, Leon Kenny, John |
Keywords: | Radiation Therapy Mobius3D Patient Dose Eclipse iPlan Lung Limitations Tolerance Levels Action Level Database Independent Verification Verifcation Programs Clinical Decision Making Treatment Planning Epworth Radiation Oncology Research Centre, Epworth HealthCare, Melbourne, VIC, Australia. Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia |
Issue Date: | Jan-2017 |
Publisher: | Wiley |
Citation: | J Appl Clin Med Phys. 2017 Jan;18(1):59-65 |
Abstract: | In radiation therapy, calculation of dose within the patient contains inherent uncertainties, inaccuracies, limitations, and the potential for random error. Thus, point dose-independent verification of such calculations is a well-established process, with published data to support the setting of both action levels and tolerances. Mobius3D takes this process one step further with a full independent calculation of patient dose and comparisons of clinical parameters such as mean target dose and voxel-by-voxel gamma analysis. There is currently no published data to directly inform tolerance levels for such parameters, and therefore this work presents a database of 1000 Mobius3D results to fill this gap. The data are tested for normality using a normal probability plot and found to fit this distribution for three sub groups of data; Eclipse, iPlan and the treatment site Lung. The mean (μ) and standard deviation (σ) of these sub groups is used to set action levels and tolerances at μ ± 2σ and μ ± 3σ, respectively. A global (3%, 3 mm) gamma tolerance is set at 88.5%. The mean target dose tolerance for Eclipse data is the narrowest at ± 3%, whilst iPlan and Lung have a range of -5.0 to 2.2% and -1.8 to 5.0%, respectively. With these limits in place, future results failing the action level or tolerance will fall within the worst 5% and 1% of historical results and an informed decision can be made regarding remedial action prior to treatment. |
URI: | http://hdl.handle.net/11434/1275 |
DOI: | 10.1002/acm2.12009 |
URL: | http://onlinelibrary.wiley.com/doi/10.1002/acm2.12009/full |
PubMed URL: | https://www.ncbi.nlm.nih.gov/pubmed/28291923 |
ISSN: | 1526-9914 |
Journal Title: | Journal of Applied Clinical Medical Physics |
Type: | Journal Article |
Type of Clinical Study or Trial: | Validation Study |
Appears in Collections: | Cancer Services |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Jolly_et_al-2017-Journal_of_Applied_Clinical_Medical_Physics.pdf | 651.35 kB | Adobe PDF | View/Open |
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.